Quinolinic Acid: An Endogenous Neurotoxin with Multiple Targets
Open accessThe DOI matches its Crossref record; 149 of the 149 references it cites were found in a registry or an index.
Abstract
Quinolinic acid (QUIN), a neuroactive metabolite of the kynurenine pathway, is normally presented in nanomolar concentrations in human brain and cerebrospinal fluid (CSF) and is often implicated in the pathogenesis of a variety of human neurological diseases. QUIN is an agonist of N-methyl-D-aspartate (NMDA) receptor, and it has a high in vivo potency as an excitotoxin. In fact, although QUIN has an uptake system, its neuronal degradation enzyme is rapidly saturated, and the rest of extracellular QUIN can continue stimulating the NMDA receptor. However, its toxicity cannot be fully explained by its activation of NMDA receptors it is likely that additional mechanisms may also be involved. In this review we describe some of the most relevant targets of QUIN neurotoxicity which involves presynaptic receptors, energetic dysfunction, oxidative stress, transcription factors, cytoskeletal disruption, behavior alterations, and cell death.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Moreover, QUIN increases the release and blocks the reuptake of glutamate in astrocytes, thus increasing glutamatergic extracellular concentrations (132).”
From Chronic stress, neuroinflammation, and depression: an overview of pathophysiological mechanisms and emerging anti-inflammatories (2023) · cites this paper as [132]
In the citing paper
“Together, this pathway may trigger hippocampal and mPFC cellular damage and volume reductions (138,144,145).”
From The Impact of Stress and Major Depressive Disorder on Hippocampal and Medial Prefrontal Cortex Morphology (2019) · cites this paper as [145]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular diversity of glutamate receptors and implications for brain function
Nakanishi, S. (1992) · Science · doi:10.1126/science.1329206 · Cited by 2,543 · cited 1×
“Areas of the brain most sensitive to QUIN neurotoxicity are the hippocampus and striatum [32] in which the NMDA receptors are widely distributed [33].”
BackgroundReplication of the neurochemical characteristics of Huntington's disease by quinolinic acid
Beal, M. F., Kowall, N. W., Ellison, D. W., Mazurek, M. F., Swartz, K. J., & Martin, J. B. (1986) · Nature · doi:10.1038/321168a0 · Cited by 1,286
Quinolinic Acid: An Endogenous Metabolite That Produces Axon-Sparing Lesions in Rat Brain
Schwarcz, R., Whetsell, W. O., & Mangano, R. M. (1983) · Science · doi:10.1126/science.6849138 · Cited by 1,263
Cytokines and endothelial cell biology
Pober, J. S., & Cotran, R. S. (1990) · Physiological Reviews · doi:10.1152/physrev.1990.70.2.427 · Cited by 1,242 · cited 1×
“Although TNF-α is not neurotoxic itself, this proinflammatory cytokine can contribute to neuronal damage through a variety of effects, such as stimulation of free radical formation, induction of cellular adhesion molecule expression, or potentiation of glutamatemediate neurotoxicity [123, 124].”
BackgroundNeuropharmacology of quinolinic and kynurenic acids.
Stone, T. W. (1993) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00441-7 · Cited by 948 · cited 3×
“Furthermore, 3-HAO activity may normally be restrained by factors such as the availability of Fe ions [8, 22, 23].”
BackgroundSchulze-Osthoff, K., Bakker, A. C., Vanhaesebroeck, B., Beyaert, R., Jacob, W. A., & Fiers, W. (1992) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)42768-8 · Cited by 939
Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS
Stone, T. W., & Perkins, M. N. (1981) · European Journal of Pharmacology · doi:10.1016/0014-2999(81)90587-2 · Cited by 751 · cited 2×
“In 1981, Stone and Perkins discovered that QUIN was a potent excitant of neurons in the CNS, by acting as an agonist at the N-methyl-D-aspartate (NMDA) sensitive population glutamate receptors [29], and Schwarcz and coworkers (1983) were the first who demonstrated that QUIN causes selective neuronal lesions, and they…”
BackgroundKynurenine Pathway Metabolites in Humans: Disease and Healthy States
Chen, Y., & Guillemin, G. J. (2009) · International Journal of Tryptophan Research · doi:10.4137/ijtr.s2097 · Cited by 628 · cited 1×
“8 nmol/g wet weight; almost 2-fold than that found in the hippocampus (1 nmol/g wet weight) [16–18].”
BackgroundSteiner, J., Walter, M., Gos, T., Guillemin, G. J., Bernstein, H.-G., Sarnyai, Z., Mawrin, C., Brisch, R., Bielau, H., zu Schwabedissen, L., et al. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-94 · Cited by 568
Guillemin, G. J., Smythe, G., Takikawa, O., & Brew, B. J. (2005) · Glia · doi:10.1002/glia.20090 · Cited by 497 · cited 3×
“As shown previously in cortical neurons, dopaminergic neurons do not produce QUIN but take it up from the microenvironment [15, 40].”
Background
Research works printed but not linked: 1
- Blanco-Ayala T Serratos-Alvarez I Orozco-Ibarra M Effect of some kynurenines under succinate deshidrogenase activity and ATP production: in vitro experimental and computational tools Neuroscience Meeting 2012 60.09 New Orleans, LA, USA Society for Neuroscience
Cited by
Ayala, A., Muñoz, M. F., & Argüelles, S. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/360438 · Cited by 6,349
“It is normally presented in nanomolar concentrations in human brain and cerebrospinal fluid (CSF) and is often implicated in the pathogenesis of a variety of human neurological diseases [399].”
BackgroundSantomasso, B. D., Park, J. H., Salloum, D., Riviere, I., Flynn, J., Mead, E., Halton, E., Wang, X., Senechal, B., Purdon, T., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-17-1319 · Cited by 942
“Neurotoxicity grade Grades 0–2 Grades 3–4 Total Univariate P Overall, n (%) 31 (58) 22 (42) 53 Age, n (%) 18–30 9 (29%) 5 (22.”
BackgroundHassamal, S. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1130989 · Cited by 578
“Moreover, QUIN increases the release and blocks the reuptake of glutamate in astrocytes, thus increasing glutamatergic extracellular concentrations (132).”
BackgroundBelleau, E. L., Treadway, M. T., & Pizzagalli, D. A. (2019) · Biological Psychiatry · doi:10.1016/j.biopsych.2018.09.031 · Cited by 550
“Together, this pathway may trigger hippocampal and mPFC cellular damage and volume reductions (138,144,145).”
Inflammation, vitamin B6 and related pathways
Ueland, P. M., McCann, A., Midttun, Ø., & Ulvik, A. (2017) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2016.08.001 · Cited by 382
Tryptophan-kynurenine pathway is dysregulated in inflammation and immune activation
Zou, M.-H. (2015) · Frontiers in Bioscience · doi:10.2741/4363 · Cited by 361
“Other toxic effects of QA through NMDA receptors have been observed, such as inflammatory events, energetic deficits, and behavioral and morphological alterations (42, 160, 174).”
BackgroundGlutamatergic Signaling Along The Microbiota-Gut-Brain Axis
Baj, A., Moro, E., Bistoletti, M., Orlandi, V., Crema, F., & Giaroni, C. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061482 · Cited by 331
“Quinolinic acid is an agonist at the N-methyl-D-aspartate (NMDA) Glu receptor and has neurotoxic proinflammatory properties [38].”
BackgroundTryptophan Metabolism by Gut Microbiome and Gut-Brain-Axis: An in silico Analysis
Kaur, H., Bose, C., & Mande, S. S. (2019) · Frontiers in Neuroscience · doi:10.3389/fnins.2019.01365 · Cited by 318
Targeting the Receptor for Advanced Glycation Endproducts (RAGE): A Medicinal Chemistry Perspective
Bongarzone, S., Savickas, V., Luzi, F., & Gee, A. D. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00058 · Cited by 313
Microglia in depression: current perspectives
Jia, X., Gao, Z., & Hu, H. (2021) · Science China Life Sciences · doi:10.1007/s11427-020-1815-6 · Cited by 282
“By converting tryptophan to kynurenine, upregulated IDO increases the kynurenine/tryptophan ratio and skews the kynurenine metabolism towards production of quinolinic acid, an NMDA receptor agonist (Lugo-Huitron et al., 2013).”
BackgroundMichaudel, C., Danne, C., Agus, A., Magniez, A., Aucouturier, A., Spatz, M., Lefevre, A., Kirchgesner, J., Rolhion, N., Wang, Y., et al. (2023) · Gut · doi:10.1136/gutjnl-2022-327337 · Cited by 260
Functional Heterogeneity within Rat Orbitofrontal Cortex in Reward Learning and Decision Making
Izquierdo, A. (2017) · The Journal of Neuroscience · doi:10.1523/jneurosci.1678-17.2017 · Cited by 258
“Comparative studies of OFC function have yielded a long history of this brain region as a locus for inhibitory control, and there is convincing recent evidence of this as well (Torregrossa et al., 2008; Mansouri et al., 2014; Bryden and Roesch, 2015; Meyer and Bucci, 2016; Hardung et al., 2017).”
BackgroundNeuroprotective Effects of Coffee Bioactive Compounds: A Review
Socała, K., Szopa, A., Serefko, A., Poleszak, E., & Wlaź, P. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010107 · Cited by 248
NAD + homeostasis in human health and disease
Zapata‐Pérez, R., Wanders, R. J. A., van Karnebeek, C. D. M., & Houtkooper, R. H. (2021) · EMBO Molecular Medicine · doi:10.15252/emmm.202113943 · Cited by 238
“…homozygous and C/HTZ: compound heterozygous. ª 2021 The Authors EMBO Molecular Medicine 13: e13943 | 2021 7 of 15 The next step in the de novo synthesis of NAD+ is carried out by the enzyme QPRT, which converts QA, a potent excitotoxic and convulsant agent (Lugo-Huitron et al, 2013), into NaMN.”
BackgroundChen, L.-M., Bao, C.-H., Wu, Y., Liang, S.-H., Wang, D., Wu, L.-Y., Huang, Y., Liu, H.-R., & Wu, H.-G. (2021) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02175-2 · Cited by 227
Bosi, A., Banfi, D., Bistoletti, M., Giaroni, C., & Baj, A. (2020) · International Journal of Tryptophan Research · doi:10.1177/1178646920928984 · Cited by 221
Mechanisms of amino acid-mediated lifespan extension in Caenorhabditis elegans
Edwards, C., Canfield, J., Copes, N., Brito, A., Rehan, M., Lipps, D., Brunquell, J., Westerheide, S. D., & Bradshaw, P. C. (2015) · BMC Genetics · doi:10.1186/s12863-015-0167-2 · Cited by 213
“In contrast, quinolinic acid addition decreased worm lifespan by 26%, as might be expected from its known neurotoxicity [60].”
BackgroundMicrobial-derived metabolites as a risk factor of age-related cognitive decline and dementia
Connell, E., Le Gall, G., Pontifex, M. G., Sami, S., Cryan, J. F., Clarke, G., Müller, M., & Vauzour, D. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-022-00548-6 · Cited by 208
“Quinolinic acid, an endogenous neurotoxin, is known to activate N-methyl-D-aspartate (NMDA) receptors, increase neuronal activity, elevate intracellular calcium concentrations and modulate BBB integrity [203].”
BackgroundHestad, K., Alexander, J., Rootwelt, H., & Aaseth, J. O. (2022) · Biomolecules · doi:10.3390/biom12070998 · Cited by 200
“Furthermore, quinolinic acid plays a role in mitochondrial dysfunction in motor neurons [41], and together, these effects could contribute to ALS symptoms [54].”
BackgroundMithaiwala, M. N., Santana-Coelho, D., Porter, G. A., & O’Connor, J. C. (2021) · Cells · doi:10.3390/cells10061548 · Cited by 190
“Likewise, QA has other non-NMDAR mediated effects that include induction of neuronal apoptosis, lesioning and death of oligodendrocytes, production of free radicals that increases ROS formation and cause lipid peroxidation, impair mitochondrial respiration that have been reviewed in detail previously [46].”
BackgroundSalminen, A. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2022.101573 · Cited by 188
Role of Kynurenine Pathway in Oxidative Stress during Neurodegenerative Disorders
Mor, A., Tankiewicz-Kwedlo, A., Krupa, A., & Pawlak, D. (2021) · Cells · doi:10.3390/cells10071603 · Cited by 187
Fujigaki, H., Yamamoto, Y., & Saito, K. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.01.011 · Cited by 178
“KYN is formed at a branch point in the KP and, subsequently, is further metabolized by at least 3 different enzymes: (1) kynurenine 3-monooxygenase (KMO), which metabolizes KYN to 3hydroxykynurenine (3-HK); (2) kynurenine aminotransferase (KAT) I, II, III, and IV, which catalyze the transamination of KYN to form kynur…”
Parrott, J. M., Redus, L., Santana-Coelho, D., Morales, J., Gao, X., & O'Connor, J. C. (2016) · Translational Psychiatry · doi:10.1038/tp.2016.200 · Cited by 174
Inflammation-Induced Tryptophan Breakdown is Related With Anemia, Fatigue, and Depression in Cancer
Lanser, L., Kink, P., Egger, E. M., Willenbacher, W., Fuchs, D., Weiss, G., & Kurz, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00249 · Cited by 169
Fuertig, R., Ceci, A., Camus, S. M., Bezard, E., Luippold, A. H., & Hengerer, B. (2016) · Bioanalysis · doi:10.4155/bio-2016-0111 · Cited by 157
O'Farrell, K., & Harkin, A. (2017) · Neuropharmacology · doi:10.1016/j.neuropharm.2015.12.004 · Cited by 164
“TDO is a homotetrameric enzyme with its expression primarily restricted to the liver in the periphery (Stone, 1993) while it is egulation of the kynurenine pathway: Relevance to neuropsychiatric g/10.1016/j.neuropharm.2015.12.004 Tryptophan Kynurenine 3-Hydroxykynurenine Quinolinic acid IDO KMO KYNU 3-Hydroxyanthranil…”
InfluentialTanaka, M., Szabó, Á., Spekker, E., Polyák, H., Tóth, F., & Vécsei, L. (2022) · Cells · doi:10.3390/cells11162607 · Cited by 153
“QUIN forms a highly reactive hydroxyl free radical and is a NMDA receptor agonist which elicits excitotoxicity [118].”
BackgroundCurrent Evidence for a Role of the Kynurenine Pathway of Tryptophan Metabolism in Multiple Sclerosis
Lovelace, M. D., Varney, B., Sundaram, G., Franco, N. F., Ng, M. L., Pai, S., Lim, C. K., Guillemin, G. J., & Brew, B. J. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00246 · Cited by 151
Impact of Microbial Metabolites on Microbiota–Gut–Brain Axis in Inflammatory Bowel Disease
Banfi, D., Moro, E., Bosi, A., Bistoletti, M., Cerantola, S., Crema, F., Maggi, F., Giron, M. C., Giaroni, C., & Baj, A. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22041623 · Cited by 173
“From a mechanistic viewpoint, QA is an agonist at the NMDA glutamate receptor and is considered as a neurotoxic pro-inflammatory molecule [284], while KynA is a natural competitive antagonist for the glycine site associated with NMDA receptor, α7nACh, and GPR35 receptors [91,267].”
BackgroundInvolvement of the kynurenine pathway in the pathogenesis of Parkinson's disease
Lim, C. K., Fernández-Gomez, F. J., Braidy, N., Estrada, C., Costa, C., Costa, S., Bessede, A., Fernandez-Villalba, E., Zinger, A., Herrero, M. T., et al. (2017) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2015.12.009 · Cited by 159
Kynurenine Pathway Metabolites in Alzheimer’s Disease
Giil, L. M., Midttun, Ø., Refsum, H., Ulvik, A., Advani, R., Smith, A. D., & Ueland, P. M. (2017) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170485 · Cited by 159
Proteomic and metabolomic profiling of urine uncovers immune responses in patients with COVID-19
Bi, X., Liu, W., Ding, X., Liang, S., Zheng, Y., Zhu, X., Quan, S., Yi, X., Xiang, N., Du, J., et al. (2022) · Cell Reports · doi:10.1016/j.celrep.2021.110271 · Cited by 158
“Quinolinate mediates ROS generation by complexing with Fe2+ (Lugo-Huitrón et al., 2013).”
BackgroundRegulation of and challenges in targeting NAD+ metabolism
Migaud, M. E., Ziegler, M., & Baur, J. A. (2024) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-024-00752-w · Cited by 162
“However, a concern is the potential to accumulate quinolinic acid, which is a neurotoxin 140 , should downstream enzymes fail to metabolize the quinolinic acid as quickly as it is produced.”
Kynurenines with Neuroactive and Redox Properties: Relevance to Aging and Brain Diseases
Reyes Ocampo, J., Lugo Huitrón, R., González-Esquivel, D., Ugalde-Muñiz, P., Jiménez-Anguiano, A., Pineda, B., Pedraza-Chaverri, J., Ríos, C., & Pérez de la Cruz, V. (2014) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2014/646909 · Cited by 151
“of QUIN through NMDA receptors have been observed like inflammatory events, energetic deficit, behavioral and morphological alterations [150, 156, 157].”
BackgroundSelf-citationNeuroinflammation-Associated Aspecific Manipulation of Mouse Predator Fear by Toxoplasma gondii
Boillat, M., Hammoudi, P., Dogga, S. K., Pagès, S., Goubran, M., Rodríguez, I., & Soldati‐Favre, D. (2020) · Cell Reports · doi:10.1016/j.celrep.2019.12.019 · Cited by 159
“gondii infection and neuropsychiatric disorders has previously been suggested to result, at least in part, from the cytokine-mediated activation of indoleamine-2,3dioxygenase (IDO), which induces tryptophan degradation, leading to increased levels of neuroactive metabolites that can disturb glutamatergic and dopaminer…”
BackgroundKynurenine pathway metabolites and enzymes involved in redox reactions
González‐Esquivel, D. F., Ortega, D. R., Pineda, B., Castro, N., Ríos, C., & de la Cruz, V. P. (2016) · Neuropharmacology · doi:10.1016/j.neuropharm.2016.03.013 · Cited by 143
Self-citationKynurenic acid in neurodegenerative disorders-unique neuroprotection or double-edged sword?
Ostapiuk, A., & Urbanska, E. M. (2022) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.13768 · Cited by 142
Aaldijk, E., & Vermeiren, Y. (2022) · Ageing Research Reviews · doi:10.1016/j.arr.2021.101556 · Cited by 142
Kynurenine 3-Monooxygenase: An Influential Mediator of Neuropathology
Parrott, J. M., & O’Connor, J. C. (2015) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2015.00116 · Cited by 123
Butyrate ameliorates quinolinic acid–induced cognitive decline in obesity models
Ge, X., Zheng, M., Hu, M., Fang, X., Geng, D., Liu, S., Wang, L., Zhang, J., Guan, L., Zheng, P., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci154612 · Cited by 130
“Obesity is associated with systemic and neuroinflammation, such as activation of macrophages and microglia (4), which promote the secretion of QA (6).”
Neuroinflammation as an etiological trigger for depression comorbid with inflammatory bowel disease
Craig, C. F., Filippone, R. T., Stavely, R., Bornstein, J. C., Apostolopoulos, V., & Nurgali, K. (2022) · Journal of Neuroinflammation · doi:10.1186/s12974-021-02354-1 · Cited by 124
“Quinolinic acid reduces the expression of astrocyte glutamate reuptake pumps while stimulating release of glutamate from astrocytes which may result in glutamate neurotoxicity and neurodegeneration [245, 246] (Fig.”
BackgroundThe Microbiota–Gut–Brain Axis: Psychoneuroimmunological Insights
Marano, G., Mazza, M., Lisci, F. M., Ciliberto, M., Traversi, G., Kotzalidis, G. D., De Berardis, D., Laterza, L., Sani, G., Gasbarrini, A., et al. (2023) · Nutrients · doi:10.3390/nu15061496 · Cited by 104
“Tryptophan is transformed into excitatory neuroactive compounds, able to antagonize n-methyl-d-aspartate receptors (NMDARs), such as kynurenic acid [78,79]: excessive concentration of these metabolites has been observed in BD patients [80].”
BackgroundAmino Acid Trp: The Far Out Impacts of Host and Commensal Tryptophan Metabolism
Grifka‐Walk, H. M., Jenkins, B. R., & Kominsky, D. J. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.653208 · Cited by 123
Arora, K., Green, M., & Prakash, S. (2020) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2020.537847 · Cited by 108
Toxoplasmosis: A pathway to neuropsychiatric disorders
Tyebji, S., Seizova, S., Hannan, A. J., & Tonkin, C. J. (2018) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2018.11.012 · Cited by 117
Prebiotic and Probiotic Modulation of the Microbiota–Gut–Brain Axis in Depression
Radford-Smith, D. E., & Anthony, D. C. (2023) · Nutrients · doi:10.3390/nu15081880 · Cited by 96
Toxin-Induced Experimental Models of Learning and Memory Impairment
More, S. V., Kumar, H., Cho, D.-Y., Yun, Y.-S., & Choi, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091447 · Cited by 120
“Apart from being a NMDA receptor agonist, it has a high in vivo potency as an excitotoxin [161].”
BackgroundFilho, A. J. M. C., Lima, C. N. D. C., Vasconcelos, S. M. M., de Lucena, D. F., Maes, M. H. J., & Macêdo, D. S. (2017) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.04.035 · Cited by 116
Zádori, D., Veres, G., Szalárdy, L., Klivényi, P., & Vécsei, L. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-170929 · Cited by 107
“QUIN is capable of inducing NOS activity in astrocytes and neurons, generating ROS via the formation of QUIN-Fe 2 + complexes, and reducing antioxidant defenses, thereby leading to oxidative stress and diminished mitochondrial function [247–252].”
Lawler, N. G., Gray, N., Kimhofer, T., Boughton, B. A., Gay, M. C. L., Yang, R., Morillon, A.-C., Chin, S., Ryan, M., Begum, S., et al. (2021) · Journal of Proteome Research · doi:10.1021/acs.jproteome.1c00052 · Cited by 113
Uraemic solutes as therapeutic targets in CKD-associated cardiovascular disease
Ravid, J. D., Kamel, M. H., & Chitalia, V. C. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00408-4 · Cited by 110
Ketamine’s effect on inflammation and kynurenine pathway in depression: A systematic review
Kopra, E., Mondelli, V., Pariante, C., & Nikkheslat, N. (2021) · Journal of Psychopharmacology · doi:10.1177/02698811211026426 · Cited by 97
“…and contributing to a signaling cascade that leads to reduced brainderived neurotropic factor (BDNF), protein synthesis, and synaptogenesis (Lugo-Huitrón et al., 2013), whereas 3-HK increases reactive oxygen species in the brain, contributing to oxidative stress and neuronal apoptosis,…”
BackgroundCytokines and tryptophan metabolites can predict depressive symptoms in pregnancy
Sha, Q., Madaj, Z. B., Keaton, S. A., Galvis, M. L. E., Smart, L., Krzyżanowski, S., Fazleabas, A. T., Leach, R. E., Postolache, T. T., Achtyes, E. D., et al. (2022) · Translational Psychiatry · doi:10.1038/s41398-022-01801-8 · Cited by 107
Molecular Characteristics of RAGE and Advances in Small-Molecule Inhibitors
Kim, H. J., Jeong, M. S., & Jang, S. B. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136904 · Cited by 110
“Excessive quinolinic acid levels have been implicated in a variety of human neurological diseases, including AD and Huntington’s disease [67].”
BackgroundThe Influence of Kynurenine Metabolites on Neurodegenerative Pathologies
Pathak, S., Nadar, R. M., Kim, S., Liu, K., Govindarajulu, M., Cook, P., Alexander, C. S. W., Dhanasekaran, M., & Moore, T. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25020853 · Cited by 104
Kynurenine Pathway Metabolites as Biomarkers in Alzheimer’s Disease
Liang, Y., Xie, S., He, Y., Xu, M., Qiao, X., Zhu, Y. H., & Wu, W. (2022) · Disease Markers · doi:10.1155/2022/9484217 · Cited by 105
Treatment-resistant depression: molecular mechanisms and management
Kajumba, M. M., Kakooza‐Mwesige, A., Nakasujja, N., Attix, D. K., & Canli, T. (2024) · Molecular Biomedicine · doi:10.1186/s43556-024-00205-y · Cited by 106
“…synthesis is associated with a corresponding decrease in the production of neuroprotective KYNA [126], and an increase in the release of pro-inflammatory mediators, including CRP [127], TNF-α and IL-6 [128], which are associated with decreased responsiveness to antidepressant treat-ment [79] (Fig.”
BackgroundNeuroinflammation: Mechanisms, Dual Roles, and Therapeutic Strategies in Neurological Disorders
García‐Domínguez, M. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47060417 · Cited by 105
The gut microbiome and Alzheimer’s disease: Complex and bidirectional interactions
Tarawneh, R. M., & Penhos, E. (2022) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2022.104814 · Cited by 97
Sethi, R., Gómez‐Coronado, N., Walker, A. J., Robertson, O. D., Agustini, B., Berk, M., & Dodd, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00605 · Cited by 100
“QUIN has also been shown to cause neurodegeneration via multiple models (159).”
BackgroundThe microbiota-gut-brain axis: Focus on the fundamental communication pathways
(2020) · Progress in Molecular Biology and Translational Science · doi:10.1016/bs.pmbts.2020.08.012 · Cited by 88
Role of enzymatic free radical scavengers in management of oxidative stress in autoimmune disorders
Srivastava, S., Singh, D., Patel, S., & Singh, M. R. (2017) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2017.03.100 · Cited by 98
Neuroinflammation and status epilepticus: a narrative review unraveling a complex interplay
Foiadelli, T., Santangelo, A., Costagliola, G., Costa, E., Scacciati, M., Riva, A., Volpedo, G., Smaldone, M. C., Bonuccelli, A., Clemente, A. M., et al. (2023) · Frontiers in Pediatrics · doi:10.3389/fped.2023.1251914 · Cited by 91
“These observations suggest that neopterin can also be produced by nerve cells under stress conditions (50).”
BackgroundBlockade of Glutamine Synthetase Enhances Inflammatory Response in Microglial Cells
Palmieri, E. M., Menga, A., Lebrun, A., Hooper, D. C., Butterfield, D. A., Mazzone, M., & Castegna, A. (2017) · Antioxidants & Redox Signaling · doi:10.1089/ars.2016.6715 · Cited by 74
“Together with glutamate, the NMDA receptor agonist, quinolinic acid, also might perpetuate continuous stimulation on NMDA receptors as its degradation system is rapidly saturated (31, 45, 76).”
BackgroundZádor, F., Joca, S. R. L., Nagy-Grócz, G., Dvorácskó, S., Szűcs, E., Tömböly, C., Benyhe, S., & Vécsei, L. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115903 · Cited by 81
“Opposite to KYNA, QUIN is an endogenous glutamate receptor agonist produced by microglia [59] and it can cause lipid peroxidation [60] and has a relevant role in the neurodegenerative process [61,62].”
BackgroundBanerjee, S., Ghosh, S., Mandal, A., Ghosh, N., & Sil, P. C. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02801-7 · Cited by 76
“In AD patients, TRP/KYN ratio and 3-HK levels increase in the plasma and serum, respectively (Lugo-Huitrón et al. 2013; Reyes Ocampo et al. 2014; Widner et al. 2000).”
BackgroundNikkheslat, N. (2021) · Brain, Behavior, & Immunity - Health · doi:10.1016/j.bbih.2021.100383 · Cited by 71
Johnston, J. N., Kadriu, B., Allen, J., Gilbert, J. R., Henter, I. D., & Zarate, C. A. (2023) · Neuropharmacology · doi:10.1016/j.neuropharm.2023.109422 · Cited by 75
Potential Role of Curcumin for the Treatment of Major Depressive Disorder
Lopresti, A. L. (2022) · CNS Drugs · doi:10.1007/s40263-022-00901-9 · Cited by 80
“In addition to releasing inflammatory mediators, microglia can also secrete glutamate and metabolise kynurenine transported to the CNS into quinolinic acid, a neurotoxic compound [140].”
BackgroundAlmulla, A. F., Supasitthumrong, T., Tunvirachaisakul, C., Algon, A. A. A., Al-Hakeim, H. K., & Maes, M. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07582-1 · Cited by 73
“TRY CAT s such as QA and XA and PA may have direct neurotoxic effects by activating hippocampal NMDAR and causing excitotoxicity with apoptosis and hippocampal shrinkage, thereby inducing neurocognitive impairments [79, 80].”
BackgroundInflammation, stress and depression: An exploration of ketamine’s therapeutic profile
Johnston, J. N., Greenwald, M. S., Henter, I. D., Kraus, C., Mkrtchian, A., Clark, N. G., Park, L. T., Gold, P. W., Zarate, C. A., & Kadriu, B. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103518 · Cited by 80
Latif-Hernandez, A., Shah, D., Ahmed, T., Lo, A. C., Callaerts-Vegh, Z., Van der Linden, A., Balschun, D., & D’Hooge, R. (2016) · Scientific Reports · doi:10.1038/srep36489 · Cited by 69
Rock, K. D., St Armour, G., Horman, B., Phillips, A., Ruis, M., Stewart, A. K., Jima, D., Muddiman, D. C., Stapleton, H. M., & Patisaul, H. B. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa046 · Cited by 69
Yan, J., Kothur, K., Mohammad, S. S., Chung, J., Patel, S., Jones, H. F., Keating, B. A., Han, V. X., Webster, R., Ardern‐Holmes, S. L., et al. (2023) · EBioMedicine · doi:10.1016/j.ebiom.2023.104589 · Cited by 69
“59,60 The longitudinal samples showed how the selected diagnostic metabolites are potentially useful in the longitudinal monitoring of neuroin fl ammation.”
Tanaka, M., Szabó, Á., & Vécsei, L. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252312767 · Cited by 58
“It exerts its toxic effects primarily through the overactivation of N-methyl-D-aspartate (NMDA) receptors, leading to an excessive influx of calcium ions into neurons [88,89,142,143].”
Garcez, M. L., Tan, V. X., Heng, B., & Guillemin, G. J. (2020) · International Journal of Tryptophan Research · doi:10.1177/1178646920978404 · Cited by 69
Jennings, M. R., Munn, D. H., & Blazeck, J. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003013 · Cited by 69
Behl, T., Kaur, I., Sehgal, A., Singh, S., Bhatia, S., Al‐Harrasi, A., Zengin, G., Bumbu, A. G., Andronie-Cioară, F. L., Nechifor, A. C., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22136737 · Cited by 68
“For the use of QUIN and KYNA in the CNS, these metabolites must be produced locally, as both are deprived of effective active transport processes and lack the ability to penetrate BBB.”
BackgroundInfluentialPermpoon, U., Moon, J., Kim, C. Y., & Nam, T. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26157616 · Cited by 241
Denihan, N. M., Kirwan, J., Walsh, B. H., Dunn, W. B., Broadhurst, D., Boylan, G. B., & Murray, D. M. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17726502 · Cited by 69
“Further downstream lies quinolinic acid, the focus of much study due to its interactions with N-methyl-D-aspartate receptors causing convulsion and excitotoxicity, therefore implicated in the pathogenesis of several human neurological diseases.(54)”
BackgroundRojewska, E., Ciapała, K., Piotrowska, A., Makuch, W., & Mika, J. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00724 · Cited by 65
“Few preliminary studies concerning possible modifications of the kynurenine pathway raise great hopes for their clinical use in the future (Majláth et al., 2013).”
BackgroundSchildknecht, S., Pape, R., Meiser, J., Karreman, C., Strittmatter, T., Odermatt, M., Cirri, E., Friemel, A., Ringwald, M., Pasquarelli, N., et al. (2015) · Antioxidants & Redox Signaling · doi:10.1089/ars.2015.6297 · Cited by 60
“The basic principles identified in the present work are not only limited to the experimental toxin, MPTP, but could also apply to endogenously formed small molecules, such as quinolinic acid (34), isoquinolines, beta-carbolines (8), or dopamine autoxidation products (2), all of which are suspected to play key roles in…”
BackgroundKedaigle, A. J., Fraenkel, E., Atwal, R. S., Wu, M., Gusella, J. F., MacDonald, M. E., Kaye, J., Finkbeiner, S. M., Mattis, V. B., Tom, C. M., et al. (2019) · Human Molecular Genetics · doi:10.1093/hmg/ddy430 · Cited by 66
“However, these compounds have other non-mitochondrial targets as well (21,22), and do not perfectly mimic the metabolic changes caused by the mutation (33).”
BackgroundWang, Y., Zhang, Y., Wang, W., Zhang, Y., Dong, X., & Liu, Y. (2025) · Metabolites · doi:10.3390/metabo15030210 · Cited by 64
Watne, L. O., Pollmann, C. T., Neerland, B. E., Quist‐Paulsen, E., Halaas, N. B., Idland, A., Hassel, B., Henjum, K., Knapskog, A., Frihagen, F., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci163472 · Cited by 60
“QA stimulates the NMDAR, implicated in the pathogenesis of psychotic disorders (24), and some delirium patients have displayed what could be potentially neurotoxic concentrations of QA.”
InfluentialChan, R. F., Turecki, G., Shabalin, A. A., Guintivano, J., Zhao, M., Xie, L. Y., van Grootheest, G., Kaminsky, Z. A., Dean, B., Penninx, B. W. J. H., et al. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.10.014 · Cited by 55
The Kynurenine Pathway in the Acute and Chronic Phases of Cerebral Ischemia
Cuartero, M. I., de la Parra, J., García‐Culebras, A., Ballesteros, I., Lizasoaín, I., & Moro, M. Á. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151214125950 · Cited by 64
“However, its well established neurotoxic capacity may also be attributed to different mechanisms, such as removal of endogenous antioxidants, inhibition of glutamate uptake by astrocytes, generation of ROS and even metabolic impairment [69, 70].”
BackgroundKong, Q., Chen, Q., Mao, X., Wang, G., Zhao, J., Zhang, H., & Chen, W. (2022) · Nutrients · doi:10.3390/nu14081615 · Cited by 59
Hosseinalizadeh, H., Mahmoodpour, M., Samadani, A. A., & Roudkenar, M. H. (2022) · Medical Oncology · doi:10.1007/s12032-022-01724-w · Cited by 61
“In addition to apoptosis triggering activity of QUIN, other physiopathological mechanisms may occur in a number of neurodegenerative diseases with high QUIN levels [50, 51].”
BackgroundYan, J., Kuzhiumparambil, U., Bandodkar, S., Dale, R. C., & Fu, S. (2021) · Clinical & Translational Immunology · doi:10.1002/cti2.1318 · Cited by 59
“Quinolinic acid is an important metabolite inducing immunosuppression and has been hypothesised to induce toxicity in brain cells(40) and interaction with glutamate neurotoxicity.(41) Further studies in common neurological diseases with possible inflammatory mechanisms such as neurodegeneration, neuropsychiatry and ne…”
BackgroundAsiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment
Loganathan, C., & Palvannan, T. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0143-9 · Cited by 59
“In addition, excessive accumulation of QA has been implicated under various neurodegenerative diseases (Alzheimer’s, Parkinson’s, multiple sclerosis), depression, stress (Suicide attempters), human immunodeficiency virus infection, ageing, brain traumatic injury and epilepsy (Lugo-Huitron et al. 2013; Perez-De La Cruz…”
BackgroundInfluentialBoczonadi, V., King, M. S., Smith, A. C., Oláhová, M., Bánsági, B., Roos, A., Eyassu, F., Borchers, C. H., Ramesh, V., Lochmüller, H., et al. (2018) · Genetics in Medicine · doi:10.1038/gim.2017.251 · Cited by 60
Tryptophan Metabolism in Atherosclerosis and Diabetes
Sudar-Milovanovic, E. M., Gluvic, Z. M., Obradovic, M. M., Zarić, B. L., & Isenović, E. R. (2021) · Current Medicinal Chemistry · doi:10.2174/0929867328666210714153649 · Cited by 60
Polyák, H., Galla, Z., Nánási, N., Cseh, E. K., Rajda, C., Veres, G., Spekker, E., Szabó, Á., Klivènyi, P., Tanaka, M., et al. (2023) · Biomedicines · doi:10.3390/biomedicines11030945 · Cited by 58
Barton, S., Navarro, S. L., Buas, M. F., Schwarz, Y., Gu, H., Djukovic, D., Raftery, D., Kratz, M., Neuhouser, M. L., & Lampe, J. W. (2015) · Food & Function · doi:10.1039/c5fo00287g · Cited by 55
Reversal of schizophrenia-like symptoms and immune alterations in mice by immunomodulatory drugs
Araújo, T. D. S., Filho, A. J. M. C., Monte, A. S., Queiroz, A. I. D. G., Cordeiro, R. C., Machado, M. D. J. S., Lima, R. D. F., de Lucena, D. F., Maes, M. H. J., & Macêdo, D. S. (2016) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2016.09.017 · Cited by 61
Savino, R., Carotenuto, M., Polito, A. N., Noia, S. D., Albenzio, M., Scarinci, A., Ambrosi, A., Sessa, F., Tartaglia, N., & Messina, G. (2020) · Brain Sciences · doi:10.3390/brainsci10090631 · Cited by 63
Javani, G., Babri, S., Farajdokht, F., Ghaffari‐Nasab, A., & Mohaddes, G. (2022) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2022.111632 · Cited by 54
Eskelund, A., Li, Y., Budac, D. P., Müller, H. K., Gulinello, M., Sanchez, C., & Wegener, G. (2017) · Journal of Neurochemistry · doi:10.1111/jnc.14043 · Cited by 52
Metadata
- Authors
- Lugo-Huitrón, R., Ugalde Muñiz, P., Pineda, B., Pedraza-Chaverrí, J., Ríos, C., & Pérez-de la Cruz, V.
- Affiliations
- Instituto Nacional de Neurología y Neurocirugía (MX)
- Departamento de Neuroquímica, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Insurgentes Sur 3877, S.S.A., 14269 México, DF, Mexico
- Laboratorio de Neuroinmunología, Instituto Nacional de Neurología y Neurocirugía Manuel Velasco Suárez, Insurgentes Sur 3877, S.S.A., 14269 México, DF, Mexico
- Departamento de Biología, Facultad de Química, Universidad Nacional Autónoma de México, 04510 México, DF, Mexico
- Venue
- Oxidative Medicine and Cellular Longevity
- Publisher
- Wiley
- Published
- 2013
- Volume
- 2013
- Pages
- 1-14
- ISSN
- 1942-0994 (ISSN-L)
- 1942-0900
- PMC
- PMC3780648
- OpenAlex
- W1991576487
- Cited by
- 394
- References
- 146
- Citations by year
- 2026: 44 · 2025: 48 · 2024: 50 · 2023: 41 · 2022: 54 · 2021: 42 · 2020: 23 · 2019: 17 · 2018: 16 · 2017: 23 · 2016: 21 · 2015: 11 · 2014: 4
- FWCI
- 0.84
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Oxidative Medicine and Cellular Longevity (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Funders
- Consejo Nacional de Ciencia y Tecnología (183867)
- Topics
- Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Amino Acid Enzymes and Metabolism
- Keywords
- quinolinic acid, kynurenine pathway, neurotoxicity, excitotoxicity, presynaptic receptors, oxidative stress, transcription factors, cytoskeleton disruption, behavioral alterations, neuronal cell death, neurological disorders
- MeSH terms
- Animals, Energy Metabolism, Humans, Inflammation, Neurotoxins, Quinolinic Acid, Oxidative Stress, Neurodegenerative Diseases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.